Results 11 to 20 of about 18,668,916 (320)

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland [PDF]

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +2 more sources

Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex [PDF]

Haematologica, 2012
Background Hemophilia is caused by deficiencies in coagulation factor VIII or IX, resulting in direct blockade of the intrinsic tenase complex and indirect blockade of the extrinsic tenase complex which is rapidly inhibited upon binding of factor Xa to ...
Raphaël Marlu, Benoît Polack
doaj   +2 more sources

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. [PDF]

New England Journal of Medicine
BACKGROUND Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has ...
S. Connolly, Mukul Sharma, Alexander T Cohen, A. Demchuk, A. Członkowska, Arne G. Lindgren, C. Molina, D. Bereczki, D. Toni, D. Seiffge, David Tanne, E. Sandset, G. Tsivgoulis, Hanne Christensen, Jan Beyer-Westendorf, J. M. Coutinho, Mark Crowther, P. Verhamme, P. Amarenco, R. Roine, R. Mikulík, Robin Lemmens, R. Veltkamp, S. Middeldorp, T. Robinson, T. Milling, Vitor Tedim-Cruz, Wilfried Lang, A. Himmelmann, Per Ladenvall, M. Knutsson, Ella Ekholm, Andrew Law, Amanda Taylor, Tetyana Karyakina, Lizhen Xu, Kate Tsiplova, Sven Poli, Bernd Kallmünzer, Christoph Gumbinger, A. Shoamanesh   +40 more
semanticscholar   +2 more sources

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors [PDF]

Clinical Pharmacology: Advances and Applications, 2015
Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj   +1 more source

News at XI: Moving Beyond Factor Xa Inhibitors.

Journal of Thrombosis and Haemostasis, 2023
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) for many indications. Currently available DOACs include dabigatran, which
J. Fredenburgh, J. Weitz
semanticscholar   +1 more source

Roles of factor Xa beyond coagulation

Journal of Thrombosis and Thrombolysis, 2021
Oral anticoagulant therapy has changed by clinical evidence that coagulation factor Xa (FXa) can be safely and effectively targeted for thromboprophylaxis. Because thrombotic and thrombo-inflammatory diseases are frequently caused by excessive activation
W. Ruf
semanticscholar   +1 more source

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study

Frontiers in Medicine, 2022
BackgroundAnti-factor Xa activity has been suggested as a surrogate parameter for judging the effectiveness of pharmacological thromboprophylaxis with low molecular weight heparins in critically ill patients.
Christoph Dibiasi, Christoph Dibiasi, Johannes Gratz, Marion Wiegele, Andreas Baierl, Eva Schaden, Eva Schaden   +6 more
doaj   +1 more source

The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents

TH Open, 2020
SARS-CoV-2 infection (COVID-19) results in local and systemic activation of inflammation and coagulation. In this review article, we will discuss the potential role of coagulation factor Xa (FXa) in the pathophysiology of COVID-19. FXa, a serine protease,
Galit H. Frydman, Michael B. Streiff, Jean M. Connors, Gregory Piazza   +3 more
doaj   +1 more source

Factor Xa Inhibitor-Related Intracranial Hemorrhage

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Since the approval of the oral factor Xa inhibitors, there have been concerns regarding the ability to neutralize their anticoagulant effects after intracranial hemorrhage (ICH). Multiple
N. Panos, A. Cook, S. John, G. M. Jones
semanticscholar   +1 more source